Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Delayed graft Clear all
Completed Not applicable Interventional

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

NCT00007787
View directory record Official record
Conditions
Kidney Transplantation, Chronic Allograft Nephropathy
Interventions
Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 15, 2026, 9:01 AM EDT
Terminated Phase 2 Interventional Results available

T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases

NCT00589602
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Secondary Myelofibrosis
Interventions
peripheral blood lymphocyte therapy, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation (TBI)
Procedure · Radiation
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Phase 2 Interventional

Advancing Transplantation Outcomes in Children

NCT06055608
View directory record Official record
Conditions
Kidney Transplant
Interventions
Sirolimus, Belatacept, Mycophenolate Mofetil, Tacrolimus (Group1), Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 26, 2010 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 15, 2026, 9:01 AM EDT
Terminated Early Phase 1 Interventional

Belatacept for Renal Transplant Recipients With Delayed Graft Function

NCT02134288
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Belatacept, Everolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 15, 2026, 9:01 AM EDT
Completed No phase listed Observational

Biomarkers of Aging as Predictors of Kidney Transplant Function

NCT02335333
View directory record Official record
Conditions
Delayed Graft Function, Other Complications of Kidney Transplant
Interventions
No treatment
Other
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2016 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Not applicable Interventional Results available

Vacuum Assisted Closure as a Treatment for Open Fractures

NCT00582361
View directory record Official record
Conditions
Orthopaedic Traumatic Open Fractures
Interventions
Standard Wound Dressing, VAC
Procedure · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Not applicable Interventional

Autologous Point-of-Care Adipose Therapy: Delayed Injury/Scar

NCT06857435
View directory record Official record
Conditions
Burns, Contracture Scar, Surgical Injury
Interventions
Full Thickness Skin Graft (FTSG), Base of wound fat graft with Split Thickness Skin Graft (STSG) Reconstruction (Autologous Layered Composite Grafting).
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

Immune Tolerance Induction After Liver Transplantation

NCT07269041
View directory record Official record
Conditions
Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions
Donor Hematopoietic Stem and Progenitor Cell Infusion
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Not applicable Interventional

Staged Kidney Transplantation During Combined Heart/Kidney Transplantation

NCT06877169
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease, End-stage Kidney Disease
Interventions
Planned delayed implantation of kidney allograft with ex vivo machine perfusion kidney preservation.
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Not applicable Interventional

Effect of Collagen Membrane on Ridge Preservation

NCT07580495
View directory record Official record
Conditions
Dehiscence, Tooth Extraction, Alveolar Bone Loss
Interventions
Minimally Invasive tooth extraction, Alveolar ridge preservation with ABCC, Resorbable collagen membrane (InterCollagen® Guide)
Procedure · Device
Lead sponsor
Debora Dias
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Active, not recruiting Not applicable Interventional

Hepatitis C Virus (HCV) Positive Kidney Grafts in HCV Negative Recipients

NCT04605679
View directory record Official record
Conditions
Kidney Failure
Interventions
Kidney Transplantation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Not listed Phase 1 Interventional

RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function

NCT03791476
View directory record Official record
Conditions
Kidney Failure
Interventions
rhC1INH, Saline Solution
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 2 Interventional Results available

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

NCT04294641
View directory record Official record
Conditions
Chronic GVHD
Interventions
Ibrutinib, ECG, PFT's, CT, Steroid pulse (prednisone), Voriconazole, Posaconazole, Azithromycin, Montelukast, Budesonide, Beclomethasone, Filgrastim, Pegfilgrastim, Erythropoietin, Transfusions, Oral/Skin biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Bethesda, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Terminated Phase 4 Interventional Results available

Tacrolimus to Sirolimus Conversion for Delayed Graft Function

NCT00931255
View directory record Official record
Conditions
Kidney Transplant, Delayed Graft Function
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Not applicable Interventional

Hepatitis C Virus (HCV) Positive Liver Grafts in HCV Negative Recipients

NCT03650920
View directory record Official record
Conditions
Liver Failure
Interventions
Liver Transplantation
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Not applicable Interventional

Autologous Point-of-Care Adipose Therapy: Recent Injury

NCT06857448
View directory record Official record
Conditions
Burns, Contracture Scar, Surgical Injury
Interventions
Split Thickness Skin Graft (STSG), Base of wound fat graft with STSG Reconstruction (Autologous Layered Composite Grafting).
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 1 Interventional

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

NCT00374933
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 15, 2026, 9:01 AM EDT
Active, not recruiting Phase 2 Interventional

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

NCT03739502
View directory record Official record
Conditions
AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
Interventions
Hyperbaric oxygen
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)

NCT02145182
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 15, 2026, 9:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 15, 2026, 9:01 AM EDT
Completed No phase listed Observational

YSPSL for Prevention of Delayed Graft Function Part A

NCT00298181
View directory record Official record
Conditions
Delayed Graft Function
Interventions
YSPSL
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Sep 15, 2026, 9:01 AM EDT